<DOC>
	<DOCNO>NCT00518297</DOCNO>
	<brief_summary>The purpose study assess effect ATV 300 mg BID PK raltegravir 400 mg BID , assess effect raltegravir 400 mg BID PK ATV 300 mg BID , ass ECG effect ATV 300 mg BID 21 day , give without raltegravir 400 mg BID .</brief_summary>
	<brief_title>DDI HV ( ATV - Merck )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Healthy male female subject age 18 45 year old body mass index ( BMI ) 18 32 kg/mÂ² Prior enrollment , subject must physical laboratory test finding within normal limit , woman childbearing potential ( WOCBP ) must negative pregnancy test Any significant acute chronic medical illness Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination . Use prescription drug overthecounter acid controller within 4 week prior study drug administration Use drug , include overthecounter medication herbal preparation within 1 week prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Antivirals / HIV</keyword>
</DOC>